Immediate Impact
37 standout
Citing Papers
Targeted protein degradation: advances in drug discovery and clinical practice
2024 Standout
Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer
2024 Standout
Works of Amit Bardia being referenced
1553O Health-related quality of life (HRQoL) in the phase III TROPiCS-02 trial of sacituzumab govitecan (SG) vs chemotherapy in HR+/HER2- metastatic breast cancer (MBC)
2022
211MO Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase II, randomised, open-label acelERA BC study
2022
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Amit Bardia | 166 | 129 | 158 | 147 | 33 | 489 | |
| Adam Chahine | 167 | 111 | 94 | 34 | 28 | 522 | |
| Cristina Ibáñez | 121 | 160 | 117 | 98 | 30 | 486 | |
| Laura Comotti | 138 | 141 | 370 | 113 | 19 | 551 | |
| Jiayin Zheng | 120 | 70 | 124 | 29 | 41 | 496 | |
| Shen Sun | 100 | 74 | 232 | 83 | 33 | 425 | |
| Nurettin Ünal | 90 | 47 | 108 | 28 | 53 | 448 | |
| Vishal Sehgal | 142 | 57 | 101 | 34 | 31 | 536 | |
| C. Marenghi | 48 | 232 | 111 | 27 | 42 | 539 | |
| B J Britton | 104 | 99 | 213 | 24 | 32 | 472 | |
| Wichit Srikureja | 39 | 92 | 171 | 73 | 27 | 441 |
All Works
Login with ORCID to disown or claim papers
Loading papers...